scholarly journals Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer

2014 ◽  
Vol 86 (1) ◽  
pp. 34-39 ◽  
Author(s):  
Azzour D. Hazzan ◽  
Hitesh H. Shah ◽  
Susana Hong ◽  
Vipulbhai Sakhiya ◽  
Rimda Wanchoo ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Erythropoiesis Stimulating Agents ◽  
Patients With Cancer

scholarly journals Intersecting Guidelines: Administering Erythropoiesis-Stimulating Agents to Chronic Kidney Disease Patients with Cancer

2009 ◽  
Vol 22 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Charles L. Bennett ◽  
Pamela S. Becker ◽  
Eric H. Kraut ◽  
Athena T. Samaras ◽  
Dennis P. West
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Erythropoiesis Stimulating Agents ◽  
Patients With Cancer

Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality

2014 ◽  
Vol 134 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Oliver Königsbrügge ◽  
Felix Lötsch ◽  
Christoph Zielinski ◽  
Ingrid Pabinger ◽  
Cihan Ay
Keyword(s):  
Chronic Kidney Disease ◽  
Venous Thromboembolism ◽  
Kidney Disease ◽  
Patients With Cancer

SO036MOLIDUSTAT INCREASES HAEMOGLOBIN IN ERYTHROPOIESIS STIMULATING AGENTS (ESA)-NAIVE ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS (CKD-ND)

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i16-i16 ◽  
Author(s):  
Iain C. Macdougall ◽  
Tadao Akizawa ◽  
Jeffrey Berns ◽  
Silvia Lentini ◽  
Thomas Bernhardt
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Erythropoiesis Stimulating Agents

A Comparative Review of Erythropoiesis Stimulating Agents

2008 ◽  
Vol 21 (6) ◽  
pp. 424-430
Author(s):  
Nicole L. Metzger ◽  
Kerry E. Francis ◽  
Stacy A. Voils
Keyword(s):  
Chronic Kidney Disease ◽  
Clinical Trials ◽  
Kidney Disease ◽  
Tumor Progression ◽  
Safety And Efficacy ◽  
Regulatory Issues ◽  
Erythropoiesis Stimulating Agents ◽  
Disease States ◽  
Comparative Review ◽  
The Us

Erythropoiesis stimulating agents have been used for more than a decade in patients with chronic kidney disease, malignancy, and other disease states where anemia is common. Recently, several clinical trials have questioned the safety and efficacy of these agents. Thrombosis and increase in tumor progression as well as a potential increase in mortality have been noted in some trials and have generated growing concern regarding whether these agents should remain on the US market. Subsequently, reimbursement from some payers for erythropoiesis stimulating agent administration has become somewhat restrictive. We address the pharmacology, pharmacokinetics, pharmacodynamics, safety, efficacy, and pharmacoeconomics of erythropoiesis stimulating agents as well as emerging regulatory issues pertaining to the administration of erythropoiesis stimulating agents.

Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease

2020 ◽  
Author(s):  
Roberto Minutolo ◽  
Carlo Garofalo ◽  
Paolo Chiodini ◽  
Filippo Aucella ◽  
Lucia Del Vecchio ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Primary Endpoint ◽  
End Stage Kidney Disease ◽  
Short Acting ◽  
Erythropoiesis Stimulating Agents ◽  
Increased Risk ◽  
Significant Difference ◽  
Long Acting ◽  
End Stage

Abstract Background Despite the widespread use of erythropoiesis-stimulating agents (ESAs) to treat anaemia, the risk of adverse outcomes associated with the use of different types of ESAs in non-dialysis chronic kidney disease (CKD) is poorly investigated. Methods From a pooled cohort of four observational studies, we selected CKD patients receiving short-acting (epoetin α/β; n = 299) or long-acting ESAs (darbepoetin and methoxy polyethylene glycol-epoetin β; n = 403). The primary composite endpoint was end-stage kidney disease (ESKD; dialysis or transplantation) or all-cause death. Multivariable Cox models were used to estimate the relative risk of the primary endpoint between short- and long-acting ESA users. Results During follow-up [median 3.6 years (interquartile range 2.1–6.3)], the primary endpoint was registered in 401 patients [166 (72%) in the short-acting ESA group and 235 (58%) in the long-acting ESA group]. In the highest tertile of short-acting ESA dose, the adjusted risk of primary endpoint was 2-fold higher {hazard ratio [HR] 2.07 [95% confidence interval (CI) 1.37–3.12]} than in the lowest tertile, whereas it did not change across tertiles of dose for long-acting ESA patients. Furthermore, the comparison of ESA type in each tertile of ESA dose disclosed a significant difference only in the highest tertile, where the risk of the primary endpoint was significantly higher in patients receiving short-acting ESAs [HR 1.56 (95% CI 1.09–2.24); P = 0.016]. Results were confirmed when ESA dose was analysed as continuous variable with a significant difference in the primary endpoint between short- and long-acting ESAs for doses >105 IU/kg/week. Conclusions Among non-dialysis CKD patients, the use of a short-acting ESA may be associated with an increased risk of ESKD or death versus long-acting ESAs when higher ESA doses are prescribed.

scholarly journals PUK23 ADHERENCE TO A GUIDELINE FOR ERYTHROPOIESIS STIMULATING AGENTS IN CHRONIC KIDNEY DISEASE

2010 ◽  
Vol 13 (3) ◽  
pp. A80
Author(s):  
YC Yeh ◽  
MD Clapp ◽  
WW Churchill ◽  
J O'Day ◽  
P Reddy
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Erythropoiesis Stimulating Agents
Sign in / Sign up

Export Citation Format

Share Document